News
Exact Sciences delivered a quarter characterized by strong year-over-year revenue growth and margin improvement, but the ...
GlobalData on MSN6d
Exact Sciences to acquire US rights for Freenome’s blood-based CRC test
Under the agreement, Exact Sciences will pay Freenome an upfront cash payment of $75m that is payable by this November.
Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...
Exact Sciences secures colorectal cancer test rights from Freenome in a $75M agreement with up to $700M milestone payouts.
Exact Sciences beat Q2 expectations, raised its 2025 forecast, and secured U.S. rights to Freenome's CRC blood tests in a ...
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a ...
Brisbane, California Friday, August 8, 2025, 10:00 Hrs [IST] ...
The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the ...
1d
EXAS Q2 Deep Dive: Portfolio Expansion and Productivity Drive Guidance Increase Amid Market Caution
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q2 CY2025, with sales ...
Cathie Wood is one of the country's best known growth investors, but sometimes, she acts like an umbrella-toting value ...
Investor's Business Daily on MSN5d
Is Exact Sciences, Down 8%, 'Throwing Good Money At Bad' In Its New Licensing Deal?
Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback